Arrowhead Pharmaceuticals Inc ARWR

Arrowhead Pharmaceuticals Inc is an American biopharmaceutical company based in Pasadena, California. Established in 1989 and operating internationally, the firm works to develop various treatments for rare and hard-to-treat genetic diseases, which are developed through the use of gene therapy. The company uses ribonucleic acid (RNA) chemistries to create therapies that trigger the RNA interference mechanism in order to inhibit the genes that cause intractable diseases.

There are various products in the firm’s pipeline at different stages of clinical development, including therapies to address hypertriglyceridemia, dyslipidemia, liver disease, cystic fibrosis, COPD, renal cell carcinoma, cardiovascular disease, Hepatitis B, and muscular dystrophy. The company is also working on the development of ARO-COV to create a therapy to address the coronavirus that causes COVID-19.

The company’s Targeted RNAi Molecule, commercialised as the TRiMTM platform, aims to enable tissue-specific targeting while retaining optimal pharmacologic activity. The firm’s technology primarily focuses on addressing the challenge of treating genetic diseases characterised by the overproduction of one or more proteins. The company collaborates with other organisations, including Horizon and Janssen, in its research endeavours. Arrowhead Pharmaceuticals Inc is listed on the NASDAQ under the ticker ARWR.

Add ARWR stock to your eToro watchlist today to monitor share price movements.